Newron Pharmaceuticals SpA Stock CBOE EUROPE EQUITIES
Equities
0QOI
IT0004147952
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
Sales 2024 * | 35.98M 38.56M 35.15M 52.77M | Sales 2025 * | 25.95M 27.82M 25.36M 38.07M | Capitalization | 156M 167M 152M 229M |
---|---|---|---|---|---|
Net income 2024 * | 7M 7.5M 6.84M 10.27M | Net income 2025 * | 4M 4.29M 3.91M 5.87M | EV / Sales 2024 * | 5.15 x |
Net Debt 2024 * | 29.11M 31.2M 28.44M 42.69M | Net Debt 2025 * | 2M 2.14M 1.95M 2.93M | EV / Sales 2025 * | 6.09 x |
P/E ratio 2024 * |
10.7
x | P/E ratio 2025 * |
35.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Newron Pharmaceuticals SpA
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
1st Jan change | Capi. | |
---|---|---|
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.95% | 31.47B | |
+54.44% | 25.24B | |
-11.92% | 15.82B | |
-9.12% | 11.96B | |
-15.02% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |
- Stock Market
- Equities
- NWRN Stock
- 0QOI Stock